Patent ID: 6821516
Filing Date: 2004-11-23
Classification: A61K,C12N,Y10S

Abstract:
A method for treating cancer, comprising administering to a patient in need of said treatment(i) macrophages having at least one of the following properties: their cytotoxic activity without IFN-&ggr; is increased by about 20 to 30% with respect to standard macrophages; their cytotoxic activity with IFN-&ggr; is increased by about 20 to about 40% with respect to standard macrophages incubated with IFN-&ggr;; deactivation of the cytotoxic activity following activation of IFN-&ggr; is such that sixty hours after activation with IFN-&ggr;, the residual cytotoxic activity is at least 30% of the maximum cytotoxic activity presented by the macrophages due to IFN-&ggr; activation, with said cytotoxic activity being measured as a percentage of the inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells; and (ii) bispecific antibodies which recognize both a) an antigen of said macrophages, and b) an antigen of a tumoral cell to be targeted by said macrophages.